You are here: Industry Insights > Novo Nordisk

News List

Torrent, Novo Nordisk India expand insulin manufacturing facility at Indrad expressbpd
December 12, 2017
Through the partnership, both the companies will continue to ensure the provision of cost-effective yet high-quality medication
Novo bags first approval for once-weekly diabetes drug pharmatimes
December 07, 2017
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies pharmafile
December 06, 2017
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and Tresiba, demonstrating the benefits they can provide to patients.
Novo Nordisk preps big obesity push, undeterred by its rivals' failures fiercepharma
November 22, 2017
Novo certainly doesn’t have to look far to find a cautionary tale when it comes to tackling—or outright creating—the obesity market.
Novo Nordisk reducing 185 jobs while adding another 70 under pricing pressure fiercepharma
November 13, 2017
Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk has decided to cut 185 jobs in its commercial organization and add another 70, a spokesperson told FiercePharma.
New US study reveals key reasons why millions of people with obesity are not receiving adequate care worldpharmanews
November 02, 2017
Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management (ACTION) Study published in Obesity,(2) the official journal of
FDA approves new insulin Fiasp® by Novo Nordisk pharmaasia
October 09, 2017
New fast-acting mealtime insulin Fiasp® by Novo Nordisk has been approved by the FDA for both type 1 and type 2 diabetes in adult patients.
Looking for insulin rebound, Novo Nordisk wins delayed FDA nod for ultrafast Fiasp fiercepharma
September 30, 2017
For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval.
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among peopl worldpharmanews
September 30, 2017
(IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes
Novo's Xultophy beats basal insulin in cutting cardiovascular risk Published on 14/09/17 at 09:49am pharmafile
September 15, 2017
Novo Nordisk has unveiled new data on its diabetes treatment Xultophy (insulin degludec/liraglutide) which supports its efficacy in reducing risk factors associated with an increased risk of developing cardiovascular disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page